ÖZLEM ERGÜL ERKEÇ
(Van Yüzüncü Yıl Üniversitesi Tıp Fakültesi, Fizyoloji Anabilim Dalı, Van.Türkiye)
Yıl: 2021Cilt: 27Sayı: 2ISSN: 1300-7157Sayfa Aralığı: 73 - 77İngilizce

0 0
Evaluation of Dose-Dependent Effects of Nesfatin-1 in Pentyleneterazole Induced Seizures in Mice
Objectives: It is well known that neuropeptides have powerful modulator effects on inhibitory and excitatory systems in the brain. Serum nesfatin-1 levels are reported to be increased in epileptic patients and experimental models of epilepsy. However, the effects of nesfatin-1 administration on acute pentylenetetrazole (PTZ)-induced seizures are unknown. The aim of this study is to investigate the dose-dependent effects of nesfatin-1 in PTZ-induced acute seizure model in mice. Methods: Animals were divided into six groups: (1) Control, (2) PTZ, (3, 4, 5, 6) PTZ+Nesfatin-1 (1, 10, 20 veya 40 μg/kg, i.p). Physiological saline (PS, 1 mL/kg, i.p) was administrated to the mice in the control group. Nesfatin-1 or PS was administered to the experimental groups. Thirty minutes after injection of nesfatin-1 or SF, PTZ (80 mg/kg, i.p) was injected into all experimental groups to induce epileptic seizures. Latencies of the first myoclonic jerk (FMJ), generalized clonic seizures (GCS), and tonic generalized extension (TGE), and duration of TGE were determined after PTZ injection. Results: No significant difference was found between the groups in terms of latencies of FMJ, GCS, TGE, and duration of TGE. Conclusion: Nesfatin-1 did not show anti or pro-convulsant effects at all doses. In conclusion, our data demonstrated that nesfatin-1 administration had no anti/pro-convulsant effect on PTZ (80 mg/kg) induced acute seizures in mice.
DergiAraştırma MakalesiErişime Açık
  • 1. Yemadje LP, Houinato D, Quet F, Druet-Cabanac M, Preux PM. Understanding the differences in prevalence of epilepsy in tropical regions. Epilepsia 2011;52(8):1376–81.
  • 2. Tang F, Hartz AMS, Bauer B. Drug-resistant epilepsy: multiple hypotheses, few answers. Front Neurol 2017;8:301.
  • 3. Kutlu G, Biçer Gömceli Y, Sanivar F, İnan LE. Türkiye’nin başkenti Ankara’da epilepsinin maliyeti. Epilepsi 2010;16(3):147–52.
  • 4. Kovac S, Walker MC. Neuropeptides in epilepsy. Neuropeptides 2013;47(6):467–75.
  • 5. Clynen E, Swijsen A, Raijmakers M, Hoogland G, Rigo JM. Neuropeptides as targets for the development of anticonvulsant drugs. Mol Neurobiol 2014;50(2):626–46.
  • 6. Dobolyi A, Kékesi KA, Juhász G, Székely AD, Lovas G, Kovács Z. Receptors of peptides as therapeutic targets in epilepsy research. Curr Med Chem 2014;21(6):764–87.
  • 7. Zhang B, Wong M. Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat. Epilepsia 2012;53(3):506–11.
  • 8. Erkec OE, Arihan O. Pentylenetetrazole kindling epilepsy model. Epilepsi 2015;21(1):6–12.
  • 9. Dhir A. Pentylenetetrazol (PTZ) kindling model of epilepsy. Curr Protoc Neurosci 2012;9(58): Unit9 37.
  • 10. Puzio I, Tymicki G, Predka H, Sleboda W, Sobczynska-Wolejszo M. Role of nesfatin-1 in the metabolism of skeletal tissues. Med Weter 2018;74(5):290–94.
  • 11. Ayada C, Toru U, Korkut Y. Nesfatin-1 and its effects on different systems. Hippokratia 2015;19(1):4–10.
  • 12. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443(7112):709–12.
  • 13. Pałasz A, Krzystanek M, Worthington J, Czajkowska B, Kostro K, Wiaderkiewicz R, et al. Nesfatin-1, a unique regulatory neuropeptide of the brain. Neuropeptides 2012;46(3):105–12.
  • 14. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 2007;28(12):2372–81.
  • 15. Aydin S, Dag E, Ozkan Y, Erman F, Dagli AF, Kilic N, et al. Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem 2009;328(1-2):49–56.
  • 16. Aydin S, Dag E, Ozkan Y, Arslan O, Koc G, Bek S, et al. Time-dependent changes in the serum levels of prolactin, nesfatin-1 and ghrelin as a marker of epileptic attacks young male patients. Peptides 2011;32(6):1276–80.
  • 17. Ergul Erkec O, Algul S, Kara M. Evaluation of ghrelin, nesfatin-1 and irisin levels of serum and brain after acute or chronic pentylenetetrazole administrations in rats using sodium valproate. Neurol Res 2018;40(11):923–9.
  • 18. Erken HA, Koc ER, Erken G, Genc O, Celik HT, Gokce EC, et al. Proconvulsant Effect of NUCB2/Nesfatin-1. Int J Pept Res Ther 2015;21(1):29–38.
  • 19. Kolgazi M, Cantali-Ozturk C, Deniz R, Ozdemir-Kumral ZN, Yuksel M, Sirvanci S, et al. Nesfatin-1 alleviates gastric damage via direct antioxidant mechanisms. J Surg Res 2015;193(1):111–8.
  • 20. Ge JF, Xu YY, Qin G, Pan XY, Cheng JQ, Chen FH. Nesfatin-1, a potent anorexic agent, decreases exploration and induces anxiety-like behavior in rats without altering learning or memory. Brain Res 2015;1629:171–81.
  • 21. Kumar A, Lalitha S, Mishra J. Hesperidin potentiates the neuroprotective effects of diazepam and gabapentin against pentylenetetrazole-induced convulsions in mice: Possible behavioral, biochemical and mitochondrial alterations. Indian J Pharmacol 2014;46(3):309–15.
  • 22. Ge JF, Xu YY, Qin G, Peng YN, Zhang CF, Liu XR, et al. Depression-like Behavior Induced by Nesfatin-1 in Rats: Involvement of Increased Immune Activation and Imbalance of Synaptic Vesicle Proteins. Front Neurosci 2015;9:429.
  • 23. Arabacı Tamer S, Koyuncuoğlu T, Karagöz A, Akakın D, Erzik C, Yüksel M, et al. The combination of nesfatin-1 and phenytoin has a synergisticeffect in improving seizure-induced neuronal damage andmemory dysfunction in rats. Acta Physiologica 2016;218(S709):9.
  • 24. Pan W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the bloodbrain barrier without saturation. Peptides 2007;28(11):2223–8.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.